Clinical Trials in Texas

Showing 4001-4020 of 11,487 trials

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

NCT03819387

This is an open-label, non-controlled study conducted in two parts - Part A (dose escalation) followed by Part B (dose expansion).

Non-Small Cell Lung CancerPancreatic CancerColorectal Cancer

Nitto BioPharma, Inc.49 participantsStarted Mar 2019

Beverly Hills, California, United States • La Jolla, California, United States • Tampa, Florida, United States +6 more locations

COMPLETEDPhase 255 miles

Study of VIB7734 for the Treatment of Moderate to Severely Active SLE

NCT04925934

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus in approximately 195 participants. The study duration will be 48 weeks, with a safety follow-up through week 56.There will be 3 parallel arms - 2 active treatment and 1 placebo.

Lupus Erythematosus, Systemic

Amgen214 participantsStarted May 2021

Upland, California, United States • Clearwater, Florida, United States • Ormond Beach, Florida, United States +64 more locations

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Study of VIB7734 for the Treatment of Moderate to Severely Active SLE

Find Trials by Condition in Texas

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.

Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)

ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Episealer® Knee System IDE Clinical Study

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

The clonoSEQ® Watch Registry

Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer

RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Metastatic Solid Cancer Clinical Trial

Adjunct Collection of Additional Biorepository Data From Patients Enrolled in Diabetic Foot Consortium (DFC) Trials